Replies to post #152780 on Biotech Values

[DewDiligence]

Behçet’s uveitis is a small orphan indication; however, XOMA/Servier’s phase-3 program in uveitis includes the much larger market for non-infectious uveitis (NIU)—see #msg-80192133.

[genisi]

I amuse I'm stating the obvious here but that pilot XOMA's trial was an open, uncontrolled, in 7 patients only, in Turkey (http://ard.bmj.com/content/71/4/563.abstract).
For the sake of comparison, this is AMGN's Kineret (a different anti IL-1 antibody, which is behind XOMA in Behçet’s disease) pilot trial - randomized, controlled, in 25 patients in US:

http://clinicaltrials.gov/ct2/show/NCT01441076?term=Beh%C3%A7et%E2%80%99s+uveitis&rank=9

Although data from that pilot study are good, I somehow get the feeling of rushing into phase III.